Happy Thanksgiving! Save 50% on Your MarketBeat All Access Subscription.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Considerations When Rolling Over a 401(k) into a Roth IRA
THE BEST BLACK FRIDAY DEAL YET (Ad)
Saudi viewers angry over apparent ban on World Cup streaming
Walmart shooting claims teen, young woman, father, mother
THE BEST BLACK FRIDAY DEAL YET (Ad)
Cuba's informal market finds new space on growing internet
Best Buy Proves Brick and Mortar is Here to Stay
THE BEST BLACK FRIDAY DEAL YET (Ad)
Bird flu prompts slaughter of 1.8M chickens in Nebraska
US-England World Cup game seen by 19.98M on US television
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Considerations When Rolling Over a 401(k) into a Roth IRA
THE BEST BLACK FRIDAY DEAL YET (Ad)
Saudi viewers angry over apparent ban on World Cup streaming
Walmart shooting claims teen, young woman, father, mother
THE BEST BLACK FRIDAY DEAL YET (Ad)
Cuba's informal market finds new space on growing internet
Best Buy Proves Brick and Mortar is Here to Stay
THE BEST BLACK FRIDAY DEAL YET (Ad)
Bird flu prompts slaughter of 1.8M chickens in Nebraska
US-England World Cup game seen by 19.98M on US television
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Considerations When Rolling Over a 401(k) into a Roth IRA
THE BEST BLACK FRIDAY DEAL YET (Ad)
Saudi viewers angry over apparent ban on World Cup streaming
Walmart shooting claims teen, young woman, father, mother
THE BEST BLACK FRIDAY DEAL YET (Ad)
Cuba's informal market finds new space on growing internet
Best Buy Proves Brick and Mortar is Here to Stay
THE BEST BLACK FRIDAY DEAL YET (Ad)
Bird flu prompts slaughter of 1.8M chickens in Nebraska
US-England World Cup game seen by 19.98M on US television
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Considerations When Rolling Over a 401(k) into a Roth IRA
THE BEST BLACK FRIDAY DEAL YET (Ad)
Saudi viewers angry over apparent ban on World Cup streaming
Walmart shooting claims teen, young woman, father, mother
THE BEST BLACK FRIDAY DEAL YET (Ad)
Cuba's informal market finds new space on growing internet
Best Buy Proves Brick and Mortar is Here to Stay
THE BEST BLACK FRIDAY DEAL YET (Ad)
Bird flu prompts slaughter of 1.8M chickens in Nebraska
US-England World Cup game seen by 19.98M on US television
NASDAQ:MCRB

Seres Therapeutics - MCRB Stock Forecast, Price & News

$7.15
+0.09 (+1.27%)
(As of 11/25/2022 08:57 PM ET)
Add
Compare
Today's Range
$7.02
$7.25
50-Day Range
$5.71
$9.05
52-Week Range
$2.50
$11.69
Volume
312,600 shs
Average Volume
963,530 shs
Market Capitalization
$890.83 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.33

Seres Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
114.5% Upside
$15.33 Price Target
Short Interest
Healthy
3.83% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.14
Upright™ Environmental Score
News Sentiment
1.39mentions of Seres Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$39,745 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($2.15) to ($0.98) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.48 out of 5 stars

Medical Sector

169th out of 1,044 stocks

Pharmaceutical Preparations Industry

76th out of 510 stocks

MCRB stock logo

About Seres Therapeutics (NASDAQ:MCRB) Stock

Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the treatment of clostridium difficile infection (CDI). It is also developing SER-155, a cultivated bacteria microbiome drug, which is Phase Ib clinical trial to reduce incidences of gastrointestinal infections, bloodstream infections, and graft versus host diseases in immunocompromised patients receiving allogeneic hematopoietic stem cell transplantation and solid organ transplants. In addition, the company engages in the development of SER-287 and SER-301 that are in Phase Ib to treat ulcerative colitis; SER-401 for patients with metastatic melanoma; and SER-262 to treat Clostridioides difficile infection. It has license and collaboration agreements with Nestec Ltd. and Memorial Sloan Kettering Cancer Center. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

Receive MCRB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Seres Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

MCRB Stock News Headlines

Seres Gets Closer To Good Times
Why Seres Therapeutics Shares Are Popping Off Today
Daily Biotech/Pharma Pulse: July 7
See More Headlines
Receive MCRB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Seres Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

MCRB Company Calendar

Last Earnings
11/02/2022
Today
11/28/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/07/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:MCRB
Fax
N/A
Employees
333
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$15.33
High Stock Price Forecast
$25.00
Low Stock Price Forecast
$9.00
Forecasted Upside/Downside
+114.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-65,580,000.00
Net Margins
-1,729.94%
Pretax Margin
-1,729.94%

Debt

Sales & Book Value

Annual Sales
$144.93 million
Book Value
$1.43 per share

Miscellaneous

Free Float
119,359,000
Market Cap
$890.83 million
Optionable
Optionable
Beta
2.81

Key Executives

  • Mr. Eric D. Shaff M.B.A. (Age 46)
    Pres, CEO & Director
    Comp: $953.1k
  • Mr. David A. Arkowitz M.B.A. (Age 61)
    Exec. VP, CFO & Head of Bus. Devel.
    Comp: $603.33k
  • Dr. Matthew R. Henn Ph.D. (Age 47)
    Exec. VP & Chief Scientific Officer
    Comp: $591.78k
  • Dr. David S. Ege Ph.D. (Age 48)
    Exec. VP & Chief Technology Officer
  • Mr. Carlo Tanzi Ph.D.
    Investor Relations Officer
  • Mr. Thomas J. DesRosier Esq. (Age 67)
    J.D., Chief Legal Officer, Exec. VP & Sec.
  • Ms. Kristin Ainsworth
    Sr. VP of Corp. Communications
  • Mr. Jeff York
    VP of HR
  • Ms. Paula A. Cloghessy SHRM-SCP (Age 50)
    SPHR, Exec. VP & Chief People Officer
  • Dr. Lisa von Moltke M.D. (Age 63)
    Exec. VP & Chief Medical Officer













MCRB Stock - Frequently Asked Questions

Should I buy or sell Seres Therapeutics stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Seres Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" MCRB shares.
View MCRB analyst ratings
or view top-rated stocks.

What is Seres Therapeutics' stock price forecast for 2023?

3 equities research analysts have issued twelve-month price objectives for Seres Therapeutics' shares. Their MCRB share price forecasts range from $9.00 to $25.00. On average, they expect the company's share price to reach $15.33 in the next twelve months. This suggests a possible upside of 114.5% from the stock's current price.
View analysts price targets for MCRB
or view top-rated stocks among Wall Street analysts.

How have MCRB shares performed in 2022?

Seres Therapeutics' stock was trading at $8.33 at the beginning of the year. Since then, MCRB shares have decreased by 14.2% and is now trading at $7.15.
View the best growth stocks for 2022 here
.

When is Seres Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 7th 2023.
View our MCRB earnings forecast
.

How were Seres Therapeutics' earnings last quarter?

Seres Therapeutics, Inc. (NASDAQ:MCRB) announced its earnings results on Wednesday, November, 2nd. The biotechnology company reported ($0.49) earnings per share for the quarter, missing analysts' consensus estimates of ($0.45) by $0.04. The biotechnology company earned $3.44 million during the quarter, compared to the consensus estimate of $12.29 million. Seres Therapeutics had a negative net margin of 1,729.94% and a negative trailing twelve-month return on equity of 305.32%.

What other stocks do shareholders of Seres Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Seres Therapeutics investors own include OPKO Health (OPK), TherapeuticsMD (TXMD), Juno Therapeutics (JUNO), NVIDIA (NVDA), Walt Disney (DIS), Alibaba Group (BABA), Novavax (NVAX), Advanced Micro Devices (AMD), Dynavax Technologies (DVAX) and Gilead Sciences (GILD).

When did Seres Therapeutics IPO?

(MCRB) raised $101 million in an IPO on Friday, June 26th 2015. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs and BofA Merrill Lynch served as the underwriters for the IPO and Leerink Partners and Canaccord Genuity were co-managers.

What is Seres Therapeutics' stock symbol?

Seres Therapeutics trades on the NASDAQ under the ticker symbol "MCRB."

Who are Seres Therapeutics' major shareholders?

Seres Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Flagship Pioneering Inc. (18.55%), Federated Hermes Inc. (14.85%), Vanguard Group Inc. (5.31%), BlackRock Inc. (5.06%), State Street Corp (2.99%) and Point72 Asset Management L.P. (0.75%). Insiders that own company stock include David S Ege and Health Ltp Fund Ge Nutritional.
View institutional ownership trends
.

How do I buy shares of Seres Therapeutics?

Shares of MCRB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Seres Therapeutics' stock price today?

One share of MCRB stock can currently be purchased for approximately $7.15.

How much money does Seres Therapeutics make?

Seres Therapeutics (NASDAQ:MCRB) has a market capitalization of $890.82 million and generates $144.93 million in revenue each year. The biotechnology company earns $-65,580,000.00 in net income (profit) each year or ($2.35) on an earnings per share basis.

How many employees does Seres Therapeutics have?

The company employs 333 workers across the globe.

How can I contact Seres Therapeutics?

Seres Therapeutics' mailing address is 200 SIDNEY STREET - 4TH FLOOR, CAMBRIDGE MA, 02139. The official website for the company is www.serestherapeutics.com. The biotechnology company can be reached via phone at (617) 945-9626 or via email at ctanzi@serestherapeutics.com.

This page (NASDAQ:MCRB) was last updated on 11/28/2022 by MarketBeat.com Staff